

Old standard or gold standard?

Re-evaluating the use of GPIIb/IIIa inhibitors
in high-risk ACS patients undergoing PCI

A SATELLITE SYMPOSIUM TO BE HELD DURING THE ESC CONGRESS 2009

Chairs

Eulogio Garcia

*Hospital Clínico
Universitario San Carlos,
Madrid, Spain*

Gilles Montalescot

*Pitié-Salpêtrière
University Hospital,
Paris, France*

September 1, 2009

14.00–15.30

**Room: Damascus, Zone 1,
Fira Gran Via, Barcelona**



Educational objectives

- To clarify the pathways involved in platelet activation and the mechanisms of action of the various types of antiplatelet therapy that can be used in combination in acute coronary syndrome patients
- To discuss the latest evidence on the use of antiplatelet therapies for high-risk acute coronary syndrome patients, including patient selection, risk stratification, choice of therapy and timing of administration
- To provide evidence-based recommendations on the use of triple antiplatelet therapy, with a focus on balancing efficacy and safety

Agenda

- 14.00** Welcome and introduction
Eulogio Garcia
- 14.05** Back to basics: Mechanisms of platelet activation and aggregation and the rationale for combination antiplatelet therapy
Meinrad Gawaz
Eberhard Karls University of Tübingen, Tübingen, Germany
- 14.20** Triple antiplatelet therapy: Relevance in an era of improved thienopyridine regimens
Franz-Josef Neumann
Heart Center Bad Krozingen, Bad Krozingen, Germany
- 14.40** Balancing efficacy and safety: GPIIb/IIIa and direct thrombin inhibitors in high-risk ACS
David Antoniucci
Careggi Hospital, Florence, Italy
- 14.55** Optimising clinical pathways in ACS: Antiplatelet regimen selection and implementation in high-risk patients
Dariusz Dudek
The University Hospital, Krakow, Poland
- 15.10** Panel discussion
- 15.25** Summary and closing remarks
Gilles Montalescot



*Make the most of this golden opportunity!
Join us in Room Damascus at 14.00 on Tuesday.*